Characterization of flavonoids with potent and subtype-selective actions on estrogen receptors alpha and beta

Bolt, Michael J.; Oceguera, Jessica; Singh, Pankaj K.; Safari, Kazem; Abbott, Derek H.; Neugebauer, Kaley A.; Mancini, Maureen G.; Gorelick, Daniel A.; Stossi, Fabio; Mancini, Michael A.

doi:10.1016/j.isci.2024.109275

Cited by 1 publication

(1 citation statement)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have suggested that the administration of estrogen therapy could potentially influence cognitive function in relation to age-related alterations in the brain (Llera-Oyola et al, 2024). Several epidemiological studies have suggested that the use of estrogen therapy among women who have undergone menopause may have demonstrated a preventive, therapeutic or potentially delaying effect on the onset of AD (Bolt et al, 2024). A notable study has indicated that the hormone estrogen possesses the capability to augment the effectiveness of tacrine, an anticholinesterase pharmaceutical utilised for the treatment of AD (Kadlecova et al, 2023).…”

Section: Modulation Of Estrogen Signallingmentioning

confidence: 99%

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Rishabh,

Rohilla,

Bansal

et al. 2024

Eur J of Neuroscience

View full text Add to dashboard Cite

In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.

show abstract

Section: Modulation Of Estrogen Signallingmentioning

confidence: 99%